Breast cancer consists of a heterogeneous mass of pathologic conditions which, for therapeutic guidance purposes, are classified as hormone receptor–positive, human EGFR2–positive (HER2+), or triple-negative groups. Here, ERBB2 is linked to breast carcinoma.